Repurposing the diuretic benzamil as an anti-osteosarcoma agent that acts by suppressing integrin/FAK/STAT3 signalling and compromising mitochondrial function.

IF 4.7 2区医学 Q2 CELL & TISSUE ENGINEERING

Bone & Joint Research Pub Date : 2024-04-04 DOI:10.1302/2046-3758.134.bjr-2023-0289.r1

Meng-Chieh Lin, Guan-Yu Chen, Hsin-Hsien Yu, Pei-Ling Hsu, Chu-Wan Lee, Chih-Cheng Cheng, Shih-Ying Wu, Bo-Syong Pan, Bor-Chyuan Su

引用次数: 0

Abstract

Osteosarcoma is the most common primary bone malignancy among children and adolescents. We investigated whether benzamil, an amiloride analogue and sodium-calcium exchange blocker, may exhibit therapeutic potential for osteosarcoma in vitro.

查看原文本刊更多论文

将利尿剂苯扎米尔重新用作抗骨肉瘤药物，通过抑制整合素/FAK/STAT3 信号和损害线粒体功能发挥作用。

骨肉瘤是儿童和青少年中最常见的原发性骨恶性肿瘤。我们研究了苯扎米尔（一种阿米洛利类似物和钠钙交换受体阻滞剂）在体外对骨肉瘤是否具有治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone & Joint Research CELL & TISSUE ENGINEERING-ORTHOPEDICS

CiteScore

7.40

自引率

23.90%

发文量

156

审稿时长

12 weeks

期刊介绍： The gold open access journal for the musculoskeletal sciences. Included in PubMed and available in PubMed Central.